Genotype variant associated with add-on memantine in bipolar II disorder

International Journal of Neuropsychopharmacology

Volumn 17, Issue 2, 2014, Pages 189-197

  Lu, Ru Band ^a,b   Lee, Sheng Yu ^a   Chen, Shiou Lan ^a   Chang, Yun Hsuan ^a,b   Chen, Shih Heng ^a   Chu, Chun Hsieh ^a   Huang, San Yuan ^c   Tzeng, Nian Sheng ^c   Wang, Chen Lin ^a   Wang, Liang Jen ^d   Lee, I Hui ^a   Yeh, Tzung Lieh ^a   Yang, Yen Kuang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

bipolar II disorder; Brain derived neurotrophic factor polymorphism; memantine; treatment

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; MEMANTINE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; BIPOLAR II DISORDER; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; NEUROPROTECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

ADULT; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HUMANS; MALE; MEMANTINE; POLYMORPHISM, GENETIC; VALPROIC ACID; YOUNG ADULT;

EID: 84891751236     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000825     Document Type: Article

References (64)

1. Akiskal HS, Pinto O (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 22:517-534, vii.
2. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK (1977) Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry 134:1227-1233.
3. Akiskal HS, Rosenthal RH, Rosenthal TL, Kashgarian M, Khani MK, Puzantian VR (1979) Differentiation of primary affective illness from situational, symptomatic and secondary depressions. Arch Gen Psychiatry 36:635-643.
4. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorder-IV-TR, 4th edn. Washington: American Psychiatric Association.
5. Angst J (1998) The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 50:143-151.
6. Angst J (2007) The bipolar spectrum. Br J Psychiatry 190:189-191.
7. Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H (2003) Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 253:236-240.
8. Benazzi F (2001a) Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients. J Affect Disord 66:13-18.
9. Benazzi F (2001b) Is 4 d the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci 25:32-34.
10. Benazzi F, Akiskal HS (2003) Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 73:33-38.
11. Beyer JL, Krishnan KR (2002) Volumetric brain imaging findings in mood disorders. Bipolar Disord 4:89-104.
12. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, Abate M, Segala M, Giacopuzzi M, Riva MA, Marchina E, Pasqualetti P, Perez J, Gennarelli M (2006) Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 16:620-624.
13. Chen SL, Tao PL, Chu CH, Chen SH, Wu HE, Tseng LF, Hong JS, Lu RB (2012) Low-dose memantine attenuated morphine addictive behaviour through its anti-inflammation and neurotrophic effects in rats. J Neuroimmune Pharmacol 7:444-453.
14. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, Lee FS (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behaviour. Science 314:140-143.
15. Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E (2008) Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 54:1254-1263.
16. Cotman CW, Berchtold NC (2002) Exercise: a behavioural intervention to enhance brain health and plasticity. Trends Neurosci 25:295-301.
17. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, Santin A, Kapczinski F (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398:215-219.
18. Drevets WC, Price JL, Simpson JR Jr., Todd RD, Reich T, Vannier M, Raichle ME (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824-827.
19. Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-29.
20. Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44:324-335.
21. Duman RS (2002) Synaptic plasticity and mood disorders. Mol Psychiatry 7(Suppl. 1):S29-S34.
22. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269.
23. Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844.
24. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F (2009) Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 43:1200-1204.
25. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F (2011) Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45:995-1004.
26. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158:100-106.
27. Govindarajan A, Rao BS, Nair D, Trinh M, Mawjee N, Tonegawa S, Chattarji S (2006) Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 103:13208-13213.
28. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
29. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
30. Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9:638-646.
31. Horstmann S, Binder EB (2009) Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124:57-73.
32. Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, Yin SJ, Lu RB (2004) Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 28:374-384.
33. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, Rice JA, Solomon DA, Keller MB (2003) The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord 73:19-32.
34. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB (2005) Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 62:1322-1330.
35. Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473-500.
36. Keck PE Jr., Hsu HA, Papadakis K, Russo J Jr. (2009) Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 32:199-204.
37. Koukopoulos A, Reginaldi D, Serra G, Sani G (2010) Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 12:348-349.
38. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D (2012) The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 136:163-166.
39. Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH (2005) Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 139B:51-53.
40. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V (2007) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61:142-144.
41. Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN (2007) Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 41:321-326.
42. Malhotra AK, Murphy GM Jr., Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796.
43. Mandelli L, Mazza M, Martinotti G, Tavian D, Colombo E, Missaglia S, Di Nicola M, De Ronchi D, Negri G, Colombo R, Janiri L, Serretti A (2010) Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. J Psychopharmacol 24:1747-1754.
44. Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, ter Meulen V, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 33:2228-2236.
45. Nakata K, Ujike H, Sakai A, Uchida N, Nomura A, Imamura T, Katsu T, Tanaka Y, Hamamura T, Kuroda S (2003) Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci Lett 337:17-20.
46. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL (2002) The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71:651-655.
47. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB (1999) Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. Am J Psychiatry 156:1094-1096.
48. Pivac N, Kim B, Nedic G, Joo YH, Kozaric-Kovacic D, Hong JP, Muck-Seler D (2009) Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. Croat Med J 50:43-48.
49. Popik P, Skolnick P (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53:791-797.
50. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J (2004) Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 28:1035-1043.
51. Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, Caloro M, Telesforo CL, Caltagirone SS, Panaccione I, Simonetti A, Demontis F, Girardi P (2012) The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 26:663-690.
52. Shimizu E, Hashimoto K, Iyo M (2004) Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet 126B:122-123.
53. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM (2000) Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 48:505-517.
54. Tang J, Xiao L, Shu C, Wang G, Liu Z, Wang X, Wang H, Bai X (2008) Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci Lett 433:98-102.
55. Tsai SJ, Hong CJ, Liou YJ (2010) Effects of BDNF polymorphisms on antidepressant action. Psychiatry Invest 7:236-242.
56. Vieta E, Suppes T (2008) Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 10:163-178.
57. Vieta E, Gastó C, Otero A, Nieto E, Vallejo J (1997) Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 38:98-101.
58. Wang Z, Li Z, Chen J, Huang J, Yuan C, Hong W, Yu S, Fang Y (2012) Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. Genes Brain Behav 11:524-528.
59. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB (2009) Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 34:2344-2357.
60. Yen CF, Chen CS, Ko CH, Yen JY, Huang CF (2007) Changes in insight among patients with bipolar I disorder: a 2-year prospective study. Bipolar Disord 9:238-242.
61. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J (2006) Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 21:433-438.
62. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
63. Zeger SL, Liang KY, Albert PS (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44:1049-1060.
64. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF (2010) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20:535-544.